# Prognostic Impact of Nutritional Status in Asymptomatic Patients With Cardiac Diseases
## – A Report From the CHART-2 Study –

Kotaro Nochioka, MD, PhD; Yasuhiko Sakata, MD, PhD; Jun Takahashi, MD, PhD;
Satoshi Miyata, PhD; Masanobu Miura, MD, PhD; Tsuyoshi Takada, MD;
Yoshihiro Fukumoto, MD, PhD; Nobuyuki Shiba, MD, PhD;
Hiroaki Shimokawa, MD, PhD for the CHART-2 Investigators

**Background:** The prognostic impact of nutritional status is poorly understood in asymptomatic patients with structural and/or functional heart diseases, classified as stage B in the ESC/AHA/ACC chronic heart failure (HF) guidelines.

**Methods and Results:** We evaluated the impact of nutrition, using the controlling nutritional status (CONUT) score, calculated by the serum albumin and total cholesterol levels, and lymphocyte number, in 3,421 stage B patients from the Chronic Heart Failure Analysis and Registry in the Tohoku District-2 Study (mean age: 66.9±12.7 years, male: 71.6%). During a median follow-up of 2.89 years, 224 patients died from cardiovascular (45%, n=102) and noncardiovascular (55%, n=123) causes and 139 experienced hospitalization for HF. Survival at 3 years in patients with CONUT 0–1 (reference, n=2,121), 2 (n=693) and ≥3 (n=607) was 95.5, 92.3, and 73.2%, respectively (P<0.001). The adjusted Cox hazard analyses revealed that the CONUT score was significantly associated with increased incidence of all-cause death (hazard ratio 1.27 per point increase; 95% confidence interval, 1.16–1.39, P<0.001). Subgroup analysis showed that per point increase in the CONUT score was significantly associated with a 17% increase in HF hospitalization in patients ≥70 years old (P=0.049), but not in those aged <70 years.

**Conclusions:** In the current stage B patients, poor nutritional status was associated with increased incidence of death for the overall population and of HF hospitalization for the elderly proportion. (*Circ J* 2013; **77**: 2318–2326)

**Key Words:** Epidemiology; Heart failure; Nutrition; Risk factors

Heart failure (HF) is a progressive disorder with severe mortality and morbidity.[1] The European Society of Cardiology (ESC), American Heart Association (AHA) and the American College of Cardiology (ACC) guideline underscores the importance of early detection and prevention in subjects at high risk for progression to symptomatic HF.[1,2] The ESC/ACC/AHA guideline classifies asymptomatic subjects with structural and/or functional heart disease as stage B, a category that is strongly associated with future development of HF.[2] It has been reported that in the US the prevalence of stage B is highest among stages A–D patients and that 34.1% of individuals older than 45 years are classified as stage B.[3] Thus, the management of stage B HF is quite important in real-world practice. In Japan also, we recently reported that the number of stage B patients was almost comparable to that of stage C/D in the Chronic Heart Failure Analysis and Registry in the Tohoku District-2 (CHART-2) study, a prospective multicenter observational study for HF in which 10,219 patients in the Tohoku district were enrolled (www.clinicaltrials.gov. Identifier: NCT00418041).[4,5] Therefore, risk stratification and management of stage B patients are warranted in the clinical setting. The progression of HF syndrome involves extracardiac disorders, including metabolic disorder and inflammation.[6,7] Undernutrition, which could be

**Table 1.** Assessment by CONUT Score

| Parameter | Score | | | |
|---|---|---|---|---|
| Serum albumin (g/ml) | ≥3.5 | 3.0–3.49 | 2.50–2.99 | <2.50 |
| Albumin score | 0 | 2 | 4 | 6 |
| TC (mg/dl) | ≥180 | 140–179 | 100–139 | <100 |
| Cholesterol score | 0 | 1 | 2 | 3 |
| Lymphocytes (count/ml) | ≥1,600 | 1,200–1,599 | 800–1,199 | <800 |
| Lymphocytes score | 0 | 1 | 2 | 3 |

The CONUT score is the sum of albumin, cholesterol, and lymphocytes scores. CONUT, controlling nutritional status; TC, total cholesterol.



**Figure 1.** Distribution of controlling nutritional status (CONUT) score in the present study (n=3,421).

caused by metabolic disorder and chronic inflammation, is an established prognostic marker when evaluated with body mass index (BMI)[8] or serum albumin level in patients with symptomatic HF.[9] However, there have been few reports investigating the prognostic impact of undernutrition in asymptomatic stage B patients. In the present study, we thus tested our hypothesis that assessment of nutritional status would be useful in risk stratification for future mortality and morbidity of stage B patients in the CHART-2 study, the largest prospective observational cohort study for HF in Japan (n=10,219).[4]

## Methods

### The CHART-2 Study
The study design and purpose of the CHART-2 Study have been previously described.[4,5] Briefly, the CHART-2 study is a multicenter, prospective observational study into which consecutive patients older than 20 years with significant coronary artery disease and those in stages B–D of the ESC/AHA/ACC guideline[2] were enrolled. The diagnosis of HF was based on the criteria of the Framingham study.[10] Enrollment began in October, 2006, and ended in March, 2010. All information, including medical history, laboratory data, and echocardiography data, were recorded in a computer database at the time of enrollment. Annual follow-up was made by clinical research coordinators by means of review of medical records, surveys and telephone interviews. The present study conformed to the Declaration of Helsinki and was approved by the local ethics

committees in the 24 participating hospitals. Written informed consent was given by all patients. Finally, we were able to enroll 10,219 patients in the CHART-2 Study.[4,5]

### Study Design
Among the 10,219 patients enrolled, there were 4,463 patients with stage B status. As mentioned later, we used the controlling nutritional status (CONUT) score to evaluate the nutritional status of each patient.[11] Because 1,042 patients (23%) had insufficient information to calculate their CONUT scores, we finally enrolled 3,421 patients with sufficient data. We examined whether nutritional status assessed by CONUT score was associated with the clinical endpoints of all-cause death and first hospitalization for HF.

### Definition of Stage B
We defined HF patients at the time of registration in the CHART-2 study according to the ESC/ACC/AHA guideline:[2] stage A is high risk for HF but without structural heart disease or symptoms of HF, stage B is asymptomatic cardiac structural and/or functional disease; stage C has HF symptoms, and stage D is severe HF. Cardiac structural or functional diseases were defined by echocardiographic and clinical findings as follows: enlarged left ventricular end-diastolic dimension (LVDd, ≥55 mm), reduced left ventricular ejection fraction (LVEF, ≤50%), thickened interventricular septum (>12 mm) and/or thickened left ventricular posterior wall (>12 mm), valvular heart disease, wall motion abnormalities, congenital abnor-

**Table 2.** Baseline Characteristics of Patients by CONUT Score

| | All (n=3,421) | CONUT score | | | P value |
|---|---|---|---|---|---|
| | | 0–1 (n=2,121) | 2 (n=693) | ≥3 (n=607) | |
| Age (years) | 66.9±12.7 | 65.8±12.3 | 68.0±12.5 | 69.2±12.7 | <0.001 |
| Male, n (%) | 2,448 (71.6) | 1,528 (28.0) | 488 (29.6) | 432 (28.8) | 0.69 |
| Serum albumin (g/ml) | 4.2±0.7 | 4.3±0.7 | 4.1±0.4 | 3.7±0.6 | – |
| TC (mg/dl) | 185±35 | 195±30 | 160±34 | 160±34 | – |
| Lymphocytes (count/ml) | 1,779±865 | 2,059±923 | 1,446±483 | 1,180±469 | – |
| BMI (kg/m²) | 24.1±4.3 | 24.4±4.5 | 23.5±3.8 | 23.4±4.3 | <0.001 |
| BMI ≥30 | 187 (5.5) | 138 (6.5) | 24 (3.5) | 25 (4.1) | 0.002 |
| Blood pressure (mmHg) | | | | | |
| Systolic | 130±18 | 131±18 | 129±18 | 129±19 | 0.001 |
| Diastolic | 75±12 | 76±12 | 74±12 | 73±12 | <0.001 |
| Heart rate (beats/min) | 70±13 | 70±13 | 69±13 | 70±14 | 0.28 |
| Current or past smoker, n (%) | 1,638 (47.9) | 1,042 (49.1) | 321 (46.2) | 275 (45.3) | 0.33 |
| Medical history, n (%) | | | | | |
| Previous MI | 1,059 (31.0) | 600 (28.3) | 241 (34.8) | 218 (35.9) | <0.001 |
| Hypertension | 2,653 (77.6) | 1,659 (78.2) | 511 (77.3) | 483 (79.6) | 0.02 |
| Dyslipidemia | 2,551 (74.6) | 1,612 (76.0) | 499 (72.0) | 440 (72.5) | 0.05 |
| Diabetes mellitus | 845 (24.7) | 507 (23.9) | 157 (22.7) | 181 (29.8) | 0.004 |
| Atrial fibrillation | 689 (20.1) | 406 (19.1) | 155 (22.4) | 128 (21.1) | 0.4 |
| Stroke | 542 (15.8) | 309 (14.6) | 113 (16.3) | 120 (19.8) | 0.008 |
| Cancer | 405 (11.8) | 207 (9.8) | 105 (15.2) | 93 (15.3) | <0.001 |
| Laboratory measurement | | | | | |
| Hemoglobin (g/dl) | 13.6±1.8 | 14.0±1.6 | 13.4±2.0 | 12.5±1.9 | <0.001 |
| Anemia, n (%) | 403 (11.8) | 133 (6.3) | 90 (13.0) | 180 (29.7) | <0.001 |
| Estimated GFR | | | | | |
| Mean | 68±23 | 69±22 | 66±20 | 64±26 | <0.001 |
| <60 ml·min⁻¹·1.73 m⁻², n (%) | 1,112 (32.5) | 621 (29.3) | 247 (35.6) | 244 (40.2) | <0.001 |
| BNP (pg/dl) | 102±159 | 80±110 | 117±167 | 160±252 | <0.001 |
| Echocardiographic abnormalities, n (%) | | | | | |
| LVDd ≥55 mm | 610 (17.8) | 353 (16.6) | 126 (18.2) | 131 (21.6) | 0.02 |
| LVEF ≤50% | 413 (12.1) | 240 (11.3) | 87 (12.6) | 86 (14.2) | 0.15 |
| IVS >12 mm and/or LVPW >12 mm | 1,277 (37.3) | 820 (38.7) | 243 (35.1) | 214 (35.3) | 0.07 |
| Valvular heart disease | 627 (18.3) | 380 (17.9) | 131 (18.9) | 116 (19.1) | 0.73 |
| Wall motion abnormalities | 933 (27.3) | 554 (26.1) | 207 (29.9) | 172 (28.3) | 0.11 |
| History of cardiac surgery | 297 (8.7) | 165 (7.8) | 64 (9.2) | 68 (11.2) | 0.03 |
| Congenital abnormalities | 78 (2.3) | 47 (2.2) | 15 (2.2) | 16 (2.6) | 0.81 |
| Current medication, n (%) | | | | | |
| ACEI or ARB | 2,191 (64.0) | 1,350 (63.6) | 445 (64.2) | 396 (65.2) | 0.77 |
| β-blocker | 1,151 (33.6) | 693 (32.7) | 244 (35.2) | 214 (35.3) | 0.31 |
| CCB | 1,649 (48.2) | 1,044 (49.2) | 322 (46.5) | 283 (46.6) | 0.31 |
| Lipid-lowering agent | 1,527 (44.6) | 919 (43.3) | 314 (45.3) | 294 (48.4) | 0.08 |

Results are expressed as mean±SD. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; BNP, brain natriuretic peptide; CCB, calcium-channel blocker; IVS, interventricular septum; GFR, glomerular filtration ratio; LVDD, left ventricular (LV) end-diastolic diameter; LVEF, LV ejection fraction; LVPW, LV posterior wall; MI, myocardial infarction. Other abbreviations as in Table 1.

malities, and previous cardiac surgery (eg, coronary artery bypass grafting).[4]

## Evaluation of Nutritional Status by CONUT Score

The CONUT score was developed by Ignacio de Ulíbarri et al in 2005 as a screening tool for undernutrition in a hospital population.[11] Three parameters are used to calculate the score: serum albumin level (g/dl), total cholesterol level (mg/dl), and total lymphocyte count (count/ml) (**Table 1**). Thus, the CONUT score enables assessment of protein reserves, caloric depletion, and immune defenses in each patient.[11]

To validate the relationship between the CONUT score and the nutritional risk index (NRI), an established nutrition score,[12] we calculated NRI as:

$$NRI = [1.519 \times \text{serum albumin (g/dl)}] + [41.7 \times \text{present weight (kg)/ideal body weight (kg)}].[12]$$

We defined "ideal body weight" as height (m)×height (m)×23.0 [ideal BMI]. BMI of 23.0 was determined from the results of our previous study on the relationship between BMI and chronic HF.[8] We evaluated the CONUT score both as a continuous variable (per 1 point increase) and as a categorical variable as

**Figure 2.** Cumulative incidence curves for (**A**) all-cause death and (**B**) first hospitalization for heart failure (HF) according to category of controlling nutritional status (CONUT) score at baseline. Vertical bars indicate SEs of the incidence estimates at 3 years of follow-up. Data shown are truncated at 3.5 years.

performed in a previous study [undernutrition degree: normal, CONUT 0–1 (reference); light, CONUT 2; moderate-severe, CONUT ≥3].[11] For the CONUT score evaluation, we obtained all blood samples from the patients when they had a clinically stable status at enrollment. Clinical status was considered stable when treatment and clinical parameters were unchanged during the previous 3 months.

The endpoints of the present study were all-cause death and the first hospitalization for HF. Cardiovascular death was defined as death attributable to a cardiovascular origin. Noncardiovascular death was defined as death for reasons other than cardiovascular origin (eg, renal, respiratory, cancer, trauma and infection). Unknown death was defined as death for which no specific morbid event classification could be assigned. For

**Table 3.** Impact of Nutritional Status on All-Cause Death and First Hospitalization for HF

| | No. of events/at risk (%) | No. of events/1,000 py | Model 1: unadjusted | | |
| --- | --- | --- | --- | --- | --- |
| | | | HR | 95% CI | P value |
| **All-cause death** | | | | | |
| CONUT score as continuous variable | 224/3,421 (6.5) | 22.7 | 1.38 | 1.29–1.48 | <0.001 |
| CONUT score as categorical variable | | | | | |
| CONUT score 0–1 | 105/2,121 (5.0) | 17.1 | 1.00 (reference) | | |
| CONUT score 2 | 38/693 (5.5) | 19.0 | 1.15 | 0.79–1.67 | 0.46 |
| CONUT score ≥3 | 81/607 (13.3) | 46.2 | 2.98 | 2.23–3.98 | <0.001 |
| **First hospitalization for HF** | | | | | |
| CONUT score as continuous variable | 127/3,421 (3.7) | 13.1 | 1.22 | 1.10–1.36 | <0.001 |
| CONUT score as categorical variable | | | | | |
| CONUT score 0–1 | 62/2,121 (2.9) | 10.3 | 1.00 (reference) | | |
| CONUT score 2 | 29/693 (4.2) | 14.8 | 1.49 | 0.96–2.31 | 0.08 |
| CONUT score ≥3 | 36/607 (5.9) | 20.5 | 2.22 | 1.48–3.36 | <0.001 |

| | Model 2: age- and sex-adjusted | | | Model 3: fully adjusted | | |
| --- | --- | --- | --- | --- | --- | --- |
| | HR | 95% CI | P value | HR | 95% CI | P value |
| **All-cause death** | | | | | | |
| CONUT score as continuous variable | 1.35 | 1.25–1.45 | <0.001 | 1.27 | 1.16–1.39 | <0.001 |
| CONUT score as categorical variable | | | | | | |
| CONUT score 0–1 | 1.00 (reference) | | | 1.00 (reference) | | |
| CONUT score 2 | 1.05 | 0.72–1.52 | 0.80 | 1.04 | 0.69–1.58 | 0.85 |
| CONUT score ≥3 | 2.61 | 1.94–3.49 | <0.001 | 1.99 | 1.39–2.85 | <0.001 |
| **First hospitalization for HF** | | | | | | |
| CONUT score as continuous variable | 1.20 | 1.07–1.33 | 0.001 | 1.02 | 0.88–1.18 | 0.77 |
| CONUT score as categorical variable | | | | | | |
| CONUT score 0–1 | 1.00 (reference) | | | 1.00 (reference) | | |
| CONUT score 2 | 1.40 | 0.90–2.18 | 0.14 | 1.13 | 0.69–1.86 | 0.62 |
| CONUT score ≥3 | 2.05 | 1.35–3.10 | 0.001 | 1.19 | 0.71–2.00 | 0.50 |

In model 3, we adjusted the model by age, sex, heart rate, diabetes mellitus, dyslipidemia, history of cancer, current or former smoking, LVEF, BNP levels, anemia, CKD, and treatment (ACEI, ARB, and β-blocker). AD, all-cause death; CI, confidence interval; CKD, chronic kidney disease; HF, heart failure; HR, hazard ratio; py, person-years. Other abbreviations as in Tables 1,2.

all patients, a single mode of death was stated. First hospitalization for HF was defined as the first hospitalization necessitated by HF and primarily for its treatment. A patient admitted for HF hospitalization had to show signs and symptoms of HF and to require treatment with intravenous diuretics. All events were reviewed and assigned by consensus of 2 independent physicians, the members of the Tohoku Heart Failure Association.[4,5] They reviewed case reports, death certificates, medical records, and summaries provided by the investigators.

## Statistical Analysis

All continuous variables are shown as mean±standard deviation. Comparisons of data among the 3 groups were performed by ANOVA test for continuous variables and by chi-square test or Fisher's exact test for dichotomous variables. Kaplan-Meier curves were plotted to evaluate the association between the CONUT score and all-cause death or first hospitalization for HF. We performed Cox proportional hazard analysis to compare the death rate for each mode of death and the rate of first hospitalization for HF. For evaluating the influence of the CONUT score on all-cause death, we constructed the following 3 Cox proportional hazard regression models: model 1, unadjusted; model 2, age- and sex-adjusted; and model 3, fully adjusted. In model 3, using step-wise selection, we excluded

the following covariates: systolic blood pressure, hypertension, obesity (BMI ≥30), history of myocardial infarction, and history of valvular heart disease, and we included the following covariates: age, sex, heart rate, smoking status (never vs. current or former smoker), diabetes mellitus, dyslipidemia, history of cancer, LVEF, brain natriuretic peptide (BNP) levels, anemia (defined as hemoglobin 12 g/dl in females, and 13 g/dl in males),[13] chronic kidney disease [CKD, defined as estimated glomerular filtration rate <60 ml·min$^{-1}$·1.73 m$^{-2}$],[14] and treatment [angiotensin-converting enzyme (ACEI), angiotensin-receptor blocker (ARB), and β-blocker].

Subgroup analysis was conducted according to age (≥70 years), sex, lipid-lowering agents, history of cancer, CKD and anemia, all of which may influence the CONUT score. The cut-off age of 70 years or older was based on the median and mode age (69 years). In the subgroup analysis, we adjusted the covariates in model 3. The assumption of proportional hazards was tested for the model, and no significant departure was found. We performed all analyses using IBM SPSS Statistics 18.0 (IBM, Somers, NY, USA). Two-sided probability values of <0.05 were considered to be statistically significant. The authors had full access to the data and give full agreement to the manuscript as written.

**Figure 3.** Relationship between the controlling nutritional status (CONUT) category and hazard ratios for the all-cause death in fully adjusted Cox regression analyses. Vertical bars represent 95% confidence intervals.

**Table 4.** Impact of Nutritional Status on Mortality Rate

| | No. of events (% of AD) | No. of events/1,000 py | CONUT score every 1 point increase | | |
| --- | --- | --- | --- | --- | --- |
| | | | HR | 95% CI | P value |
| Cardiovascular | 80 (35.7) | 8.1 | 1.13 | 0.96–1.32 | 0.14 |
| Heart failure | 21 (9.4) | 2.1 | 1.38 | 1.04–1.82 | 0.03 |
| Stroke | 26 (11.6) | 2.6 | 1.22 | 0.92–1.61 | 0.17 |
| Sudden death | 26 (11.6) | 2.6 | 0.68 | 0.35–1.33 | 0.26 |
| MI | 2 (0.9) | 0.2 | – | | |
| Other cardiovascular | 5 (2.2) | 0.5 | 1.18 | 0.98–1.42 | 0.73 |
| Noncardiovascular | 123 (54.9) | 12.4 | 1.37 | 1.22–1.54 | <0.001 |
| Cancer | 56 (25.0) | 5.7 | 1.23 | 0.99–1.51 | 0.051 |
| Other noncardiovascular | 67 (29.9) | 6.8 | 1.43 | 1.23–1.66 | <0.001 |
| Unknown | 21 (9.4) | 2.1 | 1.14 | 0.78–1.67 | 0.50 |

In the multivariable Cox proportional hazard models, we adjusted the models by age, sex, heart rate, diabetes mellitus, dyslipidemia, history of cancer, current or former smoking, LVEF, BNP levels, anemia, CKD, and treatment (ACEI, ARB, and β-blocker). Abbreviations as in Tables 1–3. Mortality rate is expressed as number of events per 1,000 py.

## Results

### Baseline Characteristics

**Figure 1** shows the distribution of the CONUT score; the mean (median) value was 1.4±1.4 (1.0) in the present population. The 3,421 patients were categorized as follows: CONUT 0–1 (n=2,121), CONUT 2 (n=693), and CONUT ≥3 (n=607). **Table 2** shows the baseline characteristics of the patients categorized by CONUT score. Mean age was 66.9±12.7 years and male patients accounted for 71.6%. Mean levels of serum albumin, total cholesterol, and lymphocytes were 4.2±0.7 (g/ml), 185±35 (mg/dl), and 1,779±865 (counts/ml), respectively. Of the 3,421 patients, LVDd ≥55 mm was noted in 610 (17.8%), echocardiographic LV hypertrophy in 413 (12.1%), valvular heart disease in 627 (18.3%), LV wall motion abnormalities in 933 (27.3%), history of cardiac surgery in 297 (8.7%), and congenital abnormalities in 78 (2.3%). As expected, patients with a CONUT score ≥3 were older and had lower BMI, lower Hb levels, and higher prevalence of cancer history. There was

no difference in sex, heart rate at baseline, smoking status, hypertension, atrial fibrillation, or the use of ACEI/ARB, β-blocker, calcium-channel blocker and lipid-lowering agents among the 3 groups (**Table 2**). **Table S1** shows the clinical characteristics of the 1,042 stage B patients who were registered in the CHART-2 study but excluded from the present study because of insufficient information for CONUT score calculation. The characteristics of these patients were comparable to those enrolled in the present study. Survival at 3 years was 93.8% in the 3,421 patients of the present study population and 94.1% in the 1,042 patients excluded from the present study (log-rank P=0.36).

### Nutritional Status and Death

During the median follow-up of 2.89 years, 224 (6.5%) patients died. As shown in **Figure 2A**, Kaplan-Meier curves revealed that the patients with CONUT score ≥3 had the highest event rate for all-cause death among the 3 groups (log-rank P<0.001). The Cox proportional hazard analyses revealed that

**Table 5.** Impact of Nutritional Status on All-Cause Death and First Hospitalization for HF

| | All-cause death | | | | | First hospitalization for HF | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | No. of events/at risk (%) | No. of events/ 1,000 py | HR | 95% CI | P value | No. of events/at risk (%) | No. of events/ 1,000 py | HR | 95% CI | P value |
| Age ≥70 years | 121/1,648 (7.3) | 26.2 | 1.26 | 1.13–1.41 | <0.001 | 60/1,648 (3.6) | 13.0 | 1.17 | 1.00–1.38 | 0.049 |
| Age <70 years | 53/1,773 (3.0) | 10.1 | 1.30 | 1.11–1.53 | 0.002 | 35/1,773 (2.0) | 6.8 | 0.70 | 0.51–0.97 | 0.03 |
| Male | 175/2,448 (7.1) | 24.6 | 1.31 | 1.18–1.46 | <0.001 | 85/2,448 (3.5) | 12.3 | 1.12 | 0.94–1.34 | 0.20 |
| Female | 49/973 (5.0) | 17.2 | 1.18 | 0.98–1.43 | 0.09 | 42/973 (4.3) | 15.2 | 0.85 | 0.65–1.11 | 0.24 |
| W/ lipid-lowering agent | 81/1,527 (5.3) | 18.3 | 1.38 | 1.16–1.63 | <0.001 | 50/1,527 (3.3) | 11.5 | 0.92 | 0.71–1.20 | 0.55 |
| W/o lipid-lowering agent | 143/1,894 (7.6) | 26.4 | 1.24 | 1.11–1.39 | <0.001 | 77/1,894 (4.1) | 14.6 | 1.06 | 0.89–1.26 | 0.53 |
| W/ history of cancer | 64/405 (15.8) | 55.8 | 1.51 | 1.21–1.88 | <0.001 | 17/405 (4.2) | 15.1 | 1.16 | 0.76–1.77 | 0.50 |
| W/o history of cancer | 160/3,016 (5.3) | 18.3 | 1.23 | 1.11–1.37 | <0.001 | 110/3,016 (3.6) | 12.7 | 0.99 | 0.85–1.17 | 0.99 |
| W/ CKD | 121/1,112 (10.9) | 37.6 | 1.24 | 1.09–1.40 | 0.001 | 70/1,112 (6.3) | 22.4 | 1.11 | 0.93–1.33 | 0.25 |
| W/o CKD | 103/2,309 (4.5) | 15.6 | 1.25 | 1.09–1.44 | 0.002 | 57/2,309 (2.5) | 8.7 | 0.92 | 0.72–1.19 | 0.53 |
| W/ anemia | 69/403 (17.1) | 62.0 | 1.41 | 1.23–1.61 | <0.001 | 32/403 (7.9) | 29.8 | 1.04 | 0.79–1.37 | 0.78 |
| W/o anemia | 155/3,018 (5.1) | 17.5 | 1.15 | 1.01–1.31 | 0.04 | 95/3,018 (3.1) | 10.8 | 1.03 | 0.86–1.23 | 0.09 |

Anemia is defined as hemoglobin 12 g/dl in females, and 13 g/dl in males. In this analysis, we included the following covariates: age, sex, heart rate, smoking status (never vs. current or former smoker), diabetes mellitus, dyslipidemia, history of cancer, LVEF, BNP levels, anemia, CKD, and treatment. w/, with; w/o, without. Other abbreviations as in Tables 2,3.

per point increase in the CONUT score was associated with increased risk of all-cause death [hazard ratio (HR): 1.38, 95% confidence interval (CI), 1.29–1.48, 1.35, 95% CI, 1.25–1.45, and 1.27,1.16–1.39 for models 1, 2, and 3, respectively] and that patients with CONUT score ≥3 had a 99% increase in the risk for all-cause death as compared with those with the 0–1 score (P<0.001) (**Table 3**, **Figure 3**).

**Table 4** shows the mortality rate and association between cause of death and CONUT score. Of the 252 deaths, 80 (35.7%) was attributed to cardiovascular origins, 123 (54.9%) to non-cardiovascular origins, and 21 (9.4%) of unknown cause. The CONUT score was significantly associated with HF and non-cardiovascular deaths (**Table 4**).

### Nutritional Status and First Hospitalization for HF
First hospitalization for HF was noted for 139 patients (3.4%) during the study period. The patients with CONUT score ≥3 had the highest incidence of hospitalization for HF among the 3 groups (log-rank P<0.001) (**Figure 2B**). However, as shown in **Table 3**, the Cox regression analyses revealed that per point increase in the CONUT score was associated with an increase in the risk of hospitalization for HF in the unadjusted (model 1) and age- and sex-adjusted model (model 2), but not in the fully adjusted model (model 3). This trend was also observed in the models using the CONUT score as a categorical variable (**Table 3**).

### Baseline Characteristics and Prognostic Impacts of CONUT Score in Stage B Patients
**Table 5** shows the subgroup analysis of associations between baseline characteristics and the impact of the CONUT score on all-cause death and hospitalization for HF. The relationships between CONUT score and the outcomes remained unaltered by sex, use of lipid-lowering agents, history of cancer, CKD, or anemia. However, the results showed that the relationships could be different according to the age category. In the patients aged 70 years or older, the HR (95% CI) of the CONUT score for hospitalization for HF was 1.17 (95% CI 1.00–1.38, P=0.049), whereas it was 0.70 (95% CI 0.51–0.97, P=0.03) in those younger than 70 years (**Table 5**).

### Correlation Between CONUT Score and the NRI
There was a significant inverse correlation between the CONUT score and the NRI (Pearson R=–0.51, P<0.01) (**Figure S1A**). In addition, Kaplan-Meier curves for all-cause death and HF hospitalization showed that low NRI (indicating undernutrition) was associated with higher events (**Figure S1B**).

## Discussion

In the present study, we examined whether nutritional status was associated with mortality and future HF in stage B patients registered in the CHART-2 Study, a multicenter prospective observational study for HF in Japan. The results showed that undernutrition was associated with an increased risk for all-cause death, HF death and noncardiovascular death among the stage B patients. Also, undernutrition was associated with increased risk for HF hospitalization in the elderly (>70 years), suggesting that nutritional status is a predictor for conversion to stage C in elderly, stage B patients.

### Nutritional Status and Death in Stage B Patients
We assessed the relationship between nutritional status and prognosis in stage B patients by using the CONUT score, which is the sum of the scores of serum albumin and total cholesterol levels, and total lymphocyte count.[11] In the present study, higher CONUT score was associated with increased numbers of all-cause death, HF death, and noncardiovascular death. The relationship between the CONUT score and the risk of all-cause death remained unchanged even after adjustment by age, use of lipid-lowering agents, history of cancer, CKD or anemia, suggesting that the score is useful for all stage B patients. In the present study, the overall survival at 3 years was 93.8%, comparable to that of stage B patients in the USA.[3] Notably, however, the survival at 3 years of the stage B patients with CONUT score ≥3 was 73.2%, which is equal to that of stage C patients in the USA.[3] Higher CONUT score reflects undernutrition and impaired inflammatory response, supporting the notion that metabolic disorder and the immune system play a crucial role in the development of cardiovascular diseases.

## Nutritional Status and First Hospitalization for HF in Stage B Patients

In the present study, we examined whether nutritional status could influence the transition from stage B to stage C as a possible non-cardiac factor, because undernutrition is well established not only as a prognostic risk factor in patients with HF but also as a major determinant of mortality after the onset of HF.[7–9]

Several previous studies have attempted to identify subjects at high risk for transition to symptomatic HF by using non-cardiac parameters. Velagaleti et al reported that the urinary albumin to creatinine ratio, as well as BNP, was a key factor for new-onset HF in 2,754 Framingham Heart Study participants.[15] Lam et al also reported that higher serum creatinine level, lower functional residual volume/forced vital capacity (FRV1/FVC) ratio, and lower hemoglobin level were associated with increased HF risk in the Framingham Heart Study's original cohort.[16] In all the study populations, no significant association was noted between CONUT score and risk of first hospitalization for HF, although patients with higher CONUT score had higher BNP levels as compared with those with lower scores. However, in patients aged 70 or older, higher CONUT score was associated with a 17% increase in first hospitalization for HF, whereas it was inversely associated with first hospitalization for HF in patients younger than 70 years (**Table 5**). This result suggests that the CONUT score is a useful predictor of conversion to stage C in elderly patients.

Although it is reasonable to note that undernutrition, which is more commonly observed in elderly patients, was associated with an increased incidence of HF hospitalization, caution is needed when interpreting the observation in patients younger than 70 years. One of the possible explanations is that overnutrition, rather than undernutrition, might be more influential on the development of HF in the younger generation. Accordingly, increased prevalence of overweight subjects in the younger population could be additional influencing factor, because obesity, especially abdominal obesity, is also an independent risk of HF and other cardiovascular diseases.[15–19] The differences in the medication use between younger and elderly populations should also be taken into consideration[20,21] (**Table S2**).

## Comparison With Other Established Nutrition Assessments

Because the CONUT score is a relatively new index, it needs to be validated with established scores. Indeed, it has been shown that the CONUT score is in good agreement with 2 other classical methods: the Subjective Global Assessment (SGA) and the Full Nutritional Assessment (FNA).[11] In the present study, we also examined the prognostic impact of the CONUT score and the NRI and found that both scores have comparable prognostic significance. Thus, we used the CONUT score to evaluate the prognostic impact of nutritional status in stage B patients (**Figures S1A,B**).

## Clinical Implications

The present study demonstrates that assessment of nutritional status by CONUT score is useful for risk stratification of stage B patients. Although patients with stage B are asymptomatic and thus their risks are less likely to be recognized and treated, the present study indicates that assessment of nutritional status with the CONUT score should be implemented in stage B patients.

## Study Limitations

Several limitations should be mentioned for the present study. First, we used the classification of the CONUT score reported in a previous study[11] and did not assess the optimal cut-off levels of the 3 parameters (serum albumin level, total cholesterol level, and total lymphocyte count). Second, classification of HF staging was done by investigators at each institution and thus may have caused classification bias. However, because all the investigators were established cardiologists and data were prospectively collected, class assignment bias should be minimal. Third, although we assessed the relationship between the undernutrition and prognosis, we did not evaluate the relationship between overnutrition and prognosis in stage B patients. Fourth, we did not exclude stage B patients with liver cirrhosis, which might have influenced the serum levels of albumin and cholesterol in the present study.

## Conclusions

In the present study, we were able to demonstrate that nutritional status was associated with increased incidence of death, indicating that the status is a key prognostic factor and thus should be assessed for risk stratification of stage B patients. A nutritional intervention trial in stage B patients is needed to confirm our findings.

## References

1. American Heart Association. Heart disease and stroke statistics–2012 update: A report from the American Heart Association. *Circulation* 2012; **125:** e12–e230.
2. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. ESC Committee for Practice Guidelines (CPG): ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology: Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). *Eur Heart J* 2008; **29:** 2388–2442.
3. Ammar KA, Jacobsen SJ, Mahoney DW, Kors JA, Redfield NM, Burnett JC Jr, et al. Prevalence and prognostic significance of heart failure stages: Application of the American College of Cardiology/American Heart Association heart failure staging criteria in the community. *Circulation* 2007; **115:** 1563–1570.
4. Shiba N, Nochioka K, Miura M, Kohno H, Shimokawa H; CHART-2 Investigators. Trend of westernization of etiology and clinical characteristics of heart failure patients in Japan: First report from the CHART-2 study. *Circ J* 2011; **75:** 823–833.
5. Miura M, Shiba N, Nochioka K, Takada T, Takahashi J, Shimokawa H; CHART-2 Investigators. Urinary albumin excretion in heart failure with preserved ejection fraction: An interim analysis of the CHART 2 study. *Eur J Heart Fail* 2012; **14:** 367–376.
6. Manabe I. Chronic inflammation links cardiovascular, metabolic and renal diseases. *Circ J* 2011; **75:** 2739–2748.
7. Anker SD, Chua TP, Ponikowski P, Harrington D, Swan JW, Kox WJ, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance of cardiac cachexia. *Cir-*

*culation* 1997; **96:** 526–534.

8. Nochioka K, Shiba N, Kohno H, Miura M, Shimokawa H. Both high and low body mass indexes are prognostic risks in Japanese patients with chronic heart failure: Implications from the CHART study. *J Card Fail* 2010; **16:** 880–887.

9. Horwich TB, Kalantar-Zadeh K, MacLellan RW, Fonarow GC. Albumin levels predict survival in patients with systolic heart failure. *Am Heart J* 2008; **155:** 883–889.

10. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: The Framingham study. *N Engl J Med* 1971; **285:** 1441–1446.

11. Ignacio de Ulíbarri J, González-Madroño A, de Villar NG, González P, González B, Mancha A, et al. CONUT: A tool for controlling nutritional status: First validation in a hospital population. *Nutr Hosp* 2005; **20:** 38–45.

12. Buzby GP, Knox LS, Crosby LO, Eisenberg JM, Haakenson CM, McNeal GE, et al. Study protocol: A randomized clinical trial of total parenteral nutrition in malnourished surgical patients. *Am J Clin Nutr* 1988; **47:** 366–381.

13. WHO scientific group. Nutritional anemias: Report of a WHO scientific group. *World Health Organ Tech Rep Ser* 1968; **405:** 5–37.

14. National Kidney Foundation: K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification. *Am J Kidney Dis* 2002; **39:** S1–S266.

15. Velagaleti RS, Gona P, Larson MG, Wang TJ, Levy D, Benjamin EJ, et al. Multimarker approach for the prediction of heart failure incidence in the community. *Circulation* 2010; **122:** 1700–1706.

16. Lam CS, Lyass A, Kraigher-Krainer E, Massaro JM, Lee DS, Ho JE, et al. Cardiac dysfunction and non-cardiac dysfunction as precursors of heart failure with reduced and preserved ejection fraction in the community. *Circulation* 2011; **124:** 24–30.

17. Miura Y, Fukumoto Y, Shiba N, Miura T, Shimada K, Iwama Y, et al. Prevalence and clinical implication of metabolic syndrome in chronic heart failure. *Circ J* 2010; **74:** 2612–2621.

18. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, et al. Obesity and the risk of heart failure. *N Engl J Med* 2002; **347:** 305–313.

19. Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: The Framingham experience. *Arch Intern Med* 2002; **162:** 1867–1872.

20. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, et al. Rosuvastatin in older patients with systolic heart failure. *N Engl J Med* 2007; **357:** 2248–2261.

21. Colucci WS, Kolias TJ, Adams KF, Armstrong WF, Ghali JK, Gottlieb SS, et al. Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: The REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial. *Circulation* 2007; **116:** 49–56.

## Supplementary Files

### Supplementary File 1

**Table S1.** Baseline Characteristics of the Patients Without Information for a CONUT Score

**Table S2.** Baseline Characteristics of the Patients According to Age

**Figure S1.** (**A**) Correlation between CONUT score and the nutritional risk index (NRI).

**Data S1.** Appendix

Please find supplementary file(s);
http://dx.doi.org/10.1253/circj.CJ-13-0127